New atypical antipsychotics. Experience and utility in the elderly

Drugs and Aging

Volumn 12, Issue 2, 1998, Pages 115-127

  Sweet, Robert A ^a,b   Pollock, Bruce G ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b Geriatric Psychopharmacology Program   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; SERTINDOLE; ZIPRASIDONE;

ADULT; AGED; CLINICAL TRIAL; DELIRIUM; DRUG EFFICACY; EXTRAPYRAMIDAL SYMPTOM; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; SEDATION; STANDING;

AGED; AGING; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CLOZAPINE; HUMANS; IMIDAZOLES; INDOLES; PIRENZEPINE; RANDOMIZED CONTROLLED TRIALS; RISPERIDONE; TREATMENT OUTCOME;

EID: 0031942030     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-199812020-00004     Document Type: Review

References (114)

1. Beers M, Avorn J, Soumerai SB, et al. Psychoactive medication use in intermediate-care facility residents. JAMA 1988; 260: 3016-20
2. Ray WA, Federspiel CF, Schaffner W. A study of antipsychotic drug use in nursing homes: epidemiologic evidence suggesting misuse. Am J Public Health 1980; 70: 485-91
3. Pollock BG, Mulsant BH. Antipsychotics in older patients: a safety perspective. Drugs Aging 1995; 6: 312-23
4. Jeste DV, Eastham JH, Lacro JP, et al. Management of late-life psychosis. J Clin Psychiatry 1996; 57: 39-45
5. Katzman R. Education and the prevalence of dementia and Alzheimer's disease. Neurology 1993; 43: 13-20
6. Dayneka NL, Garg V, Jusko WJ. Comparison of four basic models of indirect pharmacodynamic responses. J Pharmacokinet Biopharm 1993; 21: 457-78
7. Jost BC, Grossberg GT. The evolution of psychiatric symptoms in Alzheimer's disease: a natural history study. J Am Geriatr Soc 1996; 44: 1078-81
8. Drevets WC, Rubin EH. Psychotic symptoms and the longitudinal course of senile dementia of the Alzheimer type. Biol Psychiatry 1989; 25: 39-48
9. Zubenko GS, Rosen J, Sweet RA, et al. Impact of psychiatric hospitalization on behavioral complications of Alzhemier's disease. Am J Psychiatry 1992; 149: 1484-91
10. Swearer JM, Drachman DA, O'Donnell BF, et al. Troublesome and disruptive behaviors in dementia: relationships to diagnosis and disease severity. J Am Geriatr Soc 1988; 36: 784-90
11. Magni E, Binetti G, Bianchetti A, et al. Risk of mortality and institutionalization in demented patients with delusions. J Geriatr Psychiatry Neurol 1996; 9: 123-6
12. Steele C, Rovner BW, Chase GA, et al. Psychiatric symptoms and nursing home placement of patients with Alzheimer's disease. Am J Psychiatry 1990; 147: 1049-51
13. Devanand DP, Levy SR. Neuroleptic treatment of agitation and psychosis in dementia. J Geriatr Psychiatry Neurol 1995; 8 Suppl. 1: S18-27
14. Schneider LS, Pollock VE, Lyness SA. A metaanalysis of controlled trials of neuroleptic treatment in dementia. J Am Geriatr Soc 1990; 38: 553-63
15. Schneider LS, Sobin PB. Non-neuroleptic medications in the management of agitation in Alzheimer's disease and other dementia: a selective review. Int J Geriatr Psychiatry 1991; 6: 691-708
16. Abse DW, Dahlstrom WG, Hill C. The value of chemotherapy in senile mental disturbances: controlled comparison of chlorpromazine, reserpine-pipradrol, and opium. JAMA 1960; 174: 2036-42
17. Hamilton LD, Bennett JL. Acetophenazine for hyperactive geriatric patients. Geriatrics 1962; 17: 596-601
18. Hamilton LD, Bennett JL. The use of trifluoperazine in geriatric patients with chronic brain syndrome. J Am Geriatr Soc 1962; 10: 140-7
19. Sugerman AA, Williams BH, Adlerstein AM. Haloperidol in the psychiatric disorders of old age. Am J Psychiatry 1964; 120: 1190-2
20. Barnes R, Veith R, Okimoto J, et al. Efficacy of antipsychotic medications in behaviorally disturbed dementia patients. Am J Psychiatry 1982; 139: 1170-4
21. Petrie WM, Ban TA, Berney S, et al. Loxapine in psychogeriatrics: a placebo- and standard-controlled clinical investigation. J Clin Psychopharmacol 1982; 2: 122-6
22. Finkel SI, Lyons JS, Anderson RL, et al. A randomized, placebo-controlled trial of thiothixene in agitated, demented nursing home patients. Int J Geriatr Psychiatry 1995; 10: 129-36
23. Rada RT, Kellner R. Thiothixene in the treatment of geriatric patients with chronic organic brain syndrome. J Am Geriatr Soc 1976; 24: 105-7
24. Davis JM. Antipsychotic drugs. In: Kaplan HI, Sadock BJ, editors. Comprehensive textbook of psychiatry. 4th ed. Baltimore: Williams & Wilkins, 1985: 1481-513
25. 4. Neuropsychopharmacology 1992; 7: 261-84
26. Victoroff J, Zarow C, Mack WJ, et al. Physical aggression is associated with preservation of substantia nigra pars compacta in Alzheimer disease. Arch Neurol 1996; 53: 428-34
27. Lopez OL, Kaufer D, Reiter CT, et al. Relationship between CSF neurotransmitter metabolites and aggressive behavior in Alzheimer's disease. Eur J Neurol 1996; 3: 153-5
28. Sweet RA, Pollock BG, Mulsant BH, et al. Association of plasma homovanillate with behavioral symptoms in patients diagnosed with dementia: a preliminary report. Biol Psychiatry 1997; 42: 1016-23
29. Sweet RA, Nimgaonkar VL, Kamboh MI, et al. Genetic variation, psychosis, and aggression in Alzheimer's disease. Soc Neurosci Abst 1997; 23: 29
30. Sweet RA, Pollock BG, Mulsam BH, et al. D2 receptor pharmacodynamics correlate with psychosis in dementia of the Alzheimer's type. Psychopharmacol Bull 1997; 33 (3): 594
31. Palmer AM, DeKosky ST. Monoamine neurons in aging and Alzheimer's disease. J Neural Transm 1993; 91: 135-59
32. Sweet RA, Pollock BG. Neuroleptics in the elderly: guidelines for monitoring. Harvard Rev Psychiatry 1995; 2: 327-35
33. Sweet RA, Mulsant BH, Pollock BG, et al. Neuroleptic-induced parkinsonism in elderly patients diagnosed with psychotic major depression and dementia of the Alzheimer type. Am J Geriatr Psychiatry 1996; 4: 311-9
34. Weiner MF, Risser RC, Cullum CM, et al. Alzheimer's disease and its Lewy hody variant: a clinical analysis of postmortem verified cases. Am J Psychiatry 1996; 153: 1269-73
35. McKeith I, Fairbairn A, Perry R, et al. Neuroleptic sensitivity in patients with senile dementia of Lewy body type. BMJ 1992; 305: 673-8
36. Wilson JA, MacLennan WJ. Review: drug-induced parkinsonism in elderly patients. Age Ageing 1989; 18: 208-10
37. Pollock BG, Perel JM, Reynolds CF, et al. Pharmacodynamic issues relevant to geriatric psychopharmacology. J Geriatr Psychiatry Neurol 1990; 3: 221-8
38. Jeste DV, Caligiuri MP, Paulsen JS, et al. Risk of tardive dyskinesia in older patients: a prospective longitudinal study of 266 outpatients. Arch Gen Psychiatry 1995; 52: 756-65
39. Glazer WM, Morgenstern H, Doucette JT. Predicting the long-term risk of tardive dyskinesia in outpatients maintained on neuroleptic medications. J Clin Psychiatry 1993; 54: 133-9
40. Sweet RA, Mulsant BH, Gupta B, et al. Duration of neuroleptic treatment and prevalence of tardive dyskinesia in late life. Arch Gen Psychiatry 1995; 52: 478-86
41. Borison RL. Clinical efficacy of serotonin-dopamine antagonists relative to classic neuroleptics. J Clin Psychopharmacol 1995; 15 (1 Suppl. 1): 24S-9S
42. Meltzer HY. Serotonin-dopamine interactions and atypical antipsychotic drugs. Psychiatr Ann 1993; 23: 193-200
43. Carter CS, Mulsant BH, Sweet RA, et al. Risperidone use in a teaching hospital during its first year after market approval: economic and clinical implications. Psychopharmacol Bull 1995; 31: 719-25
44. Pollock BG. Recent developments in drug metabolism of relevance to psychiatrists. Harvard Rev Psychiatry 1995; 2: 204-13
45. Pollock BG, Perel JM, Altieri LP, et al. Debrisoquine hydroxylation phenotyping in geriatric psychopharmacology. Psychopharmacol Bull 1992; 28: 163-8
46. Armstrong M, Daly AK, Cholerton S, et al. Mutant debrisoquine hydroxylase genes in Parkinson's disease. Lancet 1992; 339: 1017-8
47. Smith AD, Gough AC, Leigh PN, et al. Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease. Lancet 1992; 339: 1375-7
48. Ring BJ, Callow J, Lindsay TJ, et al. Identification of the human cytochromes P450 responsible for the in vitro formation of the major oxidative metabolites of the antipsychotic agent olanzapine. J Pharmacol Exp Ther 1996; 276: 658-66
49. Nakamura K, Goto F, Ray WA, et al. Interethnic differences in genetic polymorphism of debrisoquine and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin Pharmacol Ther 1985; 38: 402-8
50. Pollock BG, Mulsant BH, Sweet RA, et al. An open pilot study of citalopram for behavioral disturbances of dementia: plasma levels and real-time observations. Am J Geriatr Psychiatry 1996; 5: 70-8
51. Grimm SW, Stams KR, Bui K. In vitro prediction of potential metabolic drug interactions for quetiapine [abstract]. Proceedings of the American Psychiatric Association (APA) 150th Annual Meeting; new research program and abstracts. San Diego (CA); 1997 May 17-22; 135
52. Ereshefsky L. Pharmacokinetics and drug interactions: update for new antipsychotics. J Clin Psychiatry 1996; 57: 12-25
53. Greenblatt DJ, Harmatz JS, Shader RI. Clinical pharmacokinetics of anxiolytics and hypnotics in the elderly: therapeutic considerations (part I). Clin Pharmacokinet 1991; 21: 165-77
54. Greenblatt DJ, Harmatz JS, Shader RI. Clinical pharmacokinetics of anxiolytics and hypnotics in the elderly: therapeutic considerations (part II). Clin Pharmacokinet 1991; 21: 262-73
55. Pollock BG. Gender differences in psychotropic drug metabolism. Psychopharmacol Bull 1997; 33: 235-41
56. Butler MA, Lang NP, Young JF, et al. Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites. Pharmacogenetics 1992; 2: 116-27
57. Zeeh J, Fuchs L, Bergmann W, et al. Influence of age, frailty and liver function on the pharmacokinetics of brofaromine. Eur J Clin Pharmacol 1996; 49: 387-91
58. 2 affinities differentiate atypical and typical antipsychotic drugs. Psychopharmacol Bull 1989; 25: 390-2
59. Chengappa KNR, Baker RW, Kreinbrook SB, et al. Clozapine use in female geriatric patients with psychosis. J Geriatr Psychiatry Neurol 1995; 8: 12-5
60. Oberholzer AF, Hendriksen C, Monsch AU, et al. Safety and effectiveness of low-dose clozapine in psychogeriatric patients: a preliminary study. Int Psychageriatr 1992; 4: 187-95
61. Salzman C, Vaccaro B, Lieff J, et al. Clozapine in older patients with psychosis and behavioral disruption. Am J Geriatr Psychiatry 1995; 3: 26-33
62. Richards SS, Sweet RA, Ganguli R. Clozapine: acute and maintenance treatment in late-life psychoses. Am J Geriatr Psychiatry 1996; 4: 377-8
63. Lew MF, Waters CH. Clozapine treatment of parkinsonism with psychosis. J Am Geriatr Soc 1995; 41: 669-71
64. Factor SA, Brown D, Molho ES, et al. Clozapine: a 2-year open trial in Parkinson's disease patients with psychosis. Neurology 1994; 44: 544-6
65. Wolters EC, Hurwitz TA, Mak E, et al. Clozapine in the treatment of parkinsonian patients with dopaminomimetic psychosis. Neurology 1990; 40: 832-4
66. Jansen ENH. Clozapine in the treatment of tremor in Parkinson's disease. Acta Neurol Scand 1994; 89: 262-5
67. Wolk SI, Douglas CJ. Clozapine treatment of psychosis in Parkinson's disease: a report of five consecutive cases. J Clin Psychiatry 1992; 53: 373-6
68. Freidman JH, Lannon MC. Clozapine in the treatment of psychosis in Parkinson's disease. Neurology 1989; 39: 1219-21
69. 2 antagonist, on parkinsonian rest tremor. Curr Ther Res 1987; 41: 298-300
70. Haring C, Fleischhacker WW, Schett P, et al. Influence of patient-related variables on clozapine plasma levels. Am J Psychiatry 1990; 147: 1471-5
71. Centorrino F, Baldessarini RJ, Flood JG, et al. Relation of leukocyte counts during clozapine treatment to serum concentrations of clozapine and metabolites. Am J Psychiatry 1995; 152: 610-2
72. Richelson E. Preclinical pharmacology of antipsychotic drugs: relationship to efficacy and side effects. J Clin Psychiatry Monograph 1994; 12: 17-20
73. 4 receptor agonist. Eur J Pharmacol 1994; 269: R1-2
74. Vasile JS, Steingard S. Clozapine and the development of salivary gland swelling: a case study. J Clin Psychiatry 1945; 56: 511-3
75. Honigfeld G. The clozapine national registry system: forty years of risk management. J Clin Psychiatry Monograph 1996; 14: 29-32
76. Alvir JJ, Lieberman JA, Safferman AZ, et al. Clozapine-induced agranulocytosis: incidence and risk factors in the United States. N Engl J Med 1993; 329: 162-7
77. Madhusoodanan S, Brenner R, Araujo L, et al. Efficacy of risperidone treatment for psychoses associated with schizophrenia, schizoaffective disorder, bipolar disorder, or senile dementia in 11 geriatric patients: a case series. J Cli Psychiatry 1995; 56: 514-8
78. Jeanblanc W, Davis YB. Risperidone for treating dementia-associated aggression [letter]. Am J Psychiatry 1995; 152: 1239
79. Aronson SM, Lingam V, Hasanat KA. Risperidone in geropsychiatry: review of early experience in two public hospitals [abstract]. Proceedings of the American Psychiatric Association (APA) 148th Annual Meeting: new research program and abstracts. Miami: 1995 May 20-25; 127
80. Borison RL, Davidson M, Berman I. Risperidone treatment in elderly patients with schizophrenia or dementia. Proceedings of the American Psychiatric Association (APA) 46th Institute of Hospital and Community Psychiatry; 1994
81. Goldberg RJ. Risperidone for dementia-related disturbed behavior in nursing home residents: a clinical experience [abstract]. Proceedings of the American Psychiatric Association (APA) 148th Annual Meeting: new research program and abstracts. Miami; 1995 May 20-25; 126
82. Brecher M. Risperidone in the treatment of psychosis in elderly patients [abstract]. Eighth congress of the International Psychogeriatric Association: Jerusalem: 1997 Aug 17-22: 83
83. Meco G, Alessandria A, Bonifati V, et al. Risperidone for hallucinations in levodopa-treated Parkinson's disease patients. Lancet 1994; 343: 1370-1
84. Ford B, Lynch T, Greene P. Risperidone in Parkinson's disease [letter; comment]. Lancet 1994; 344: 681
85. McKeith IG, Ballard CG, Harrison RWS. Neuroleptic sensitivity to risperidone in Lewy body dementia [letter; comment]. Lancet 1995; 346: 699
86. Rich SS, Friedman JH, Ou BR. Risperidone versus clozapine in the treatment of psychosis in six patients with Parkinson's disease and other akinetic-rigid syndromes. J Clin Psychiatry 1995; 56: 556-9
87. Berman I, Merson A, Allan H, et al. Effect of risperidone on cognitive performance in elderly schizophrenic patients: a double blind comparison study with haloperidol. Psychopharmacol Bull 1995; 31: 552
88. Huang ML, Peer AV, Woestenborghs R, et al. Pharmacokinetics and drug disposition: pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects. Clin Pharmacol Ther 1993; 54: 257-68
89. Ereshelsky L, Lacombe S. Pharmacological profile of risperidone. Can J Psychiatry 1993: 38 Suppl. 3: S80-8
90. Heykants J, Huang ML, Mannens G, et al. The pharmacokinetics of risperidone in humans: a summary. J Clin Psychiatry 1994; 55: 13-7
91. Hoffman DW, Winer MST, Bartels S, et al. Therapeutic dose : serum level relationships of risperidone and active metabolite in a geriatric population. Psychopharmacol Bull 1995; 37 (3): 525
92. Snoeck E, Peer AV, Sack M, et al. Influence of age, renal and liver impairment on the pharmacokinetics of risperidone in man. Psychopharmacology 1995; 122: 223-9
93. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994; 151: 825-35
94. 2 receptors. Psychopharmacology Berl 1993; 112 (1 Suppl.): S40-54
95. Sweet RA, Pollock BG, Mulsant BH, et al. Atypical neuroleptics: pharmacologic considerations. Eur Neuropsychopharmacol 1996; 6: 27-8
96. Satterlee WG, Reams S, Burns PR, et al. A clinical update on olanzapine treatment in schizophrenia and in elderly Alzheimer's disease patients. Psychopharmacol Bull 1995; 35 (3): 534
97. Beasley CMJ. Efficacy of olanzapine: an overview of pivotal clinical trials. J Clin Psychiatry Monograph 1997; 15: 16-8
98. Wolters EC, Jansen ENH, Tuynman-Qua HG, et al. Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's disease. Neurology 1996; 47: 1082-7
99. Ring BJ, Binkley SN, Vandenbranden M, et al. In vitro interaction ot the antipsychotic agent olanzapine with human cytochromes P450 CYP2C9, CYP2CI9, CYP2D6 and CYP3A. Br J Clin Pharmacol 1996; 41: 181-6
100. Sonne J, Loft S, Dossing M, et al. Single dose pharmacokinetics and pharmacodynamics of oral oxazepam in very elderly institutionalized subjects. Br J Clin Pharmacol 1991; 31: 719-22
101. Fisman M, Inaba T, Kalow W, et al. Oxazepam as a probe of hepatic metabolism in patients with Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry 1988; 12: 255-61
102. Bymaster FP. In vitro and in vivo biochemistry of olanzapine. J Clin Psychiatry Monograph 1997; 15: 10-2
103. van Kammen DP, McEvoy JP, Targum SD, et al. A randomized, controlled, dose-ranging trial of sertindole in patients with schizophrenia. Psychopharmacology 1996; 124: 168-75
104. Targum SD, Arvanitis LA. Quetiapine: efficacy, safely, and tolerability in elderly subjects with psychotic disorders. Psychopharmacol Bull 1997; 33 (3): 595
105. Stip E, Lussier I, Babai M, et al. Seroquel and cognitive improvement in patients with schizophrenia. Biol Psychiatry 1996; 40: 430-7
106. Thyrum PT, Jaskiw G, Fuller M, et al. Multiple-dose pharmacokinetics of ICI 204,636 in elderly patients with selected psychotic disorders [abstract]. Psychopharmacol Bull 1996; 32: 524
107. Wong JYW, Ewing BJ, Thyrum PT, et al. The effect of phenytoin and cimetidine on the pharmacokinetics of quetiapine [abstract]. Proceedings of the American Psychiatric Association (APA) 150th Annual Meeting; new research program and abstracts. San Diego (CA); 1997 May 17-22: 135
108. Schotte A, Luyten WHML, Van Compel P, et al. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology 1996; 124: 57-73
109. Seeger TF, Seymour PA, Schmidt AW, et al. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J Pharmacol Exp Ther 1995; 275: 101-13
110. Wilner KD, Anziano RJ, Johnson AC, et al. Anxiolytic effects of ziprasidone compared with diazepam and placebo prior to dental surgery [abstract]. Eur Neuropsychopharmacol 1996; 6 Suppl. 3: 117
111. Meyers BS, Greenberg R. Late-life delusional depression. J Affective Disord 1986; 11: 133-7
112. Zubenko GS, Mulsant BH, Rifai AH, et al. Impact of acute psychiatric inpatient treatment on major depression in late life and prediction of response. Am J Psychiatry 1994; 151: 987-94
113. Wilner KD, Hansen RA, Johnson AC, et al. Single and multiple dose pharmacokinetics of ziprasidone in healthy males [abstract]. Eur Neuropsychopharmacol 1996; 6 Suppl. 3: 38
114. Brook S, Swift R, Harrigan EP, et al. The tolerability and efficacy of intramuscular ziprasidone. Psychopharmacol Bull 1997; 33 (3): 498